The following IPOs are expected to price this week:
Diamond Resorts International (DRII), a timeshare company with more than 490,000 members and 296 destinations, plans to raise $264 million by offering 15.5 million shares at a price range of $16.00 to $18.00. At the midpoint of the proposed range, Diamond Resorts International would command a market value of $1.2 billion. Diamond Resorts International, which was founded in 1996, booked $568 million in sales over the last 12 months. The Las Vegas, NV-based company plans to list on the NYSE under the symbol DRII. Credit Suisse, BofA Merrill Lynch, J.P. Morgan and Guggenheim Securities are the joint bookrunners on the deal.
NRG Yield (NYLD), which owns conventional, renewable and thermal power generation assets, plans to raise $392 million by offering 19.6 million shares at a price range of $19.00 to $21.00. At the midpoint of the proposed range, NRG Yield would command a market value of $1.3 billion. NRG Yield, which was founded in 2012, booked $184 million in sales over the last 12 months. The Princeton, NJ-based company plans to list on the NYSE under the symbol NYLD. BofA Merrill Lynch, Goldman Sachs and Citi are the joint bookrunners on the deal.
OncoMed Pharmaceuticals (OMED), a biotech developing new antibody therapeutics to be used in cancer treatments, plans to raise $60 million by offering 4.0 million shares at a price range of $14.00 to $16.00. At the midpoint of the proposed range, OncoMed Pharmaceuticals would command a market value of $394 million. OncoMed Pharmaceuticals, which was founded in 2004, booked $25 million in sales over the last 12 months. The Redwood City, CA-based company plans to list on the NASDAQ under the symbol OMED. Jefferies & Co. and Leerink Swann are the joint bookrunners on the deal.
Physicians Realty Trust (DOC), a rEIT focused on acquiring, developing and managing healthcare properties, plans to raise $100 million by offering 8.0 million shares at a price range of $11.50 to $13.50. At the midpoint of the proposed range, Physicians Realty Trust would command a market value of $137 million. Physicians Realty Trust, which was founded in 2013, booked $13 million in sales over the last 12 months. The Milwaukee, WI-based company plans to list on the NYSE under the symbol DOC. Wunderlich Securities, Oppenheimer & Co., Janney Montgomery Scott and JMP Securities are the joint bookrunners on the deal.
RetailMeNot (SALE), which operates the largest digital coupon sites in the US and the UK, plans to raise $191 million by offering 9.1 million shares at a price range of $20.00 to $22.00. At the midpoint of the proposed range, RetailMeNot would command a market value of $1.1 billion. RetailMeNot, which was founded in 2007, booked $156 million in sales over the last 12 months. The Austin, TX-based company plans to list on the NASDAQ under the symbol SALE. Morgan Stanley, Goldman Sachs, Credit Suisse and Jefferies & Co. are the joint bookrunners on the deal.
Rexford Industrial Realty (REXR), a REIT focused on owning and operating industrial properties in Southern California, plans to raise $224 million by offering 16.0 million shares at a price range of $13.00 to $15.00. At the midpoint of the proposed range, Rexford Industrial Realty would command a market value of $353 million. Rexford Industrial Realty, which was founded in 2013, booked $35 million in sales over the last 12 months. The Los Angeles, CA-based company plans to list on the NYSE under the symbol REXR. BofA Merrill Lynch, Wells Fargo Securities, FBR Capital Markets and J.P. Morgan are the joint bookrunners on the deal.
UCP (UCP), a homebuilder and land developer in Northern CA and Puget Sound, WA, plans to raise $124 million by offering 7.8 million shares at a price range of $15.00 to $17.00. At the midpoint of the proposed range, UCP would command a market value of $300 million. UCP, which was founded in 2004, booked $66 million in sales over the last 12 months. The San Jose, CA-based company plans to list on the NYSE under the symbol UCP. Citi, Deutsche Bank and Zelman Partners LLC are the joint bookrunners on the deal.
Renaissance Capital will have Pre-IPO Research available on each of these upcoming IPOs prior to its pricing.
